Lineage Cell Therapeutics Inc
ASE:LCTX 11:19:56 AM EDT
Products, Regulatory
Lineage Cell Provides Update On OPC1 Cell Therapy Program For Treatment Of Spinal Cord Injury
Published: 12/08/2020 13:29 GMT
Lineage Cell Therapeutics Inc (LCTX) - Lineage Cell Therapeutics Inc - Provides Update on Opc1 Cell Therapy Program for Treatment of Spinal Cord Injury.
Lineage Cell Therapeutics Inc - Major Improvements Made to Opc1 Production, Including to Process, Purity, Potency, and Scale.
Lineage Cell Therapeutics - Filing of Patent Applications on Process, Product Which, If Allowed, Anticipated to Have Expiration Dates in 2039 and 2040.
Lineage Cell Therapeutics Inc - Major Improvements Made to Opc1 Production, Including to Process, Purity, Potency, and Scale.
Lineage Cell Therapeutics - Filing of Patent Applications on Process, Product Which, If Allowed, Anticipated to Have Expiration Dates in 2039 and 2040.